ANG Lifesciences India Limited
BSE: ANG · Pharmaceuticals · sector
₹32.84BSE close 2026-10-26
Key numbers
Market cap₹43 cr
Price₹32.84
52w high / low₹50 / ₹18
P/E3.2xSector median 27.9x
P/B0.8xSector median 2.9x
Book value₹40.5
Dividend yield–Sector median 0.48%
ROE-22.8%Sector median 11.7%
ROCE-5.8%Sector median 12.3%
OPM-2.3%Sector median 14.0%
Debt / equity1.47xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-0.9x
Current ratio0.97x
Sales growth 3y-23.4%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.01x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹4 cr vs borrowings ₹78 cr (FY26): borrowings are higher by ₹74 cr.
- Operating profit covered interest -0.9x in the last 12 months.
- Net loss in 6 of the last 6 quarters.
- Dividend paid in 1 of the last 5 financial years.
- Price ₹32.84 on 2026-10-26: -33.9% from the 52-week high, +86.3% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹55.20 · low ₹20.26
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 17 | 25 | 26 | 19 | 24 | 15 |
| EBITDA | -1 | 1 | 0 | -3 | 3 | -2 |
| OPM % | -4.2% | 2.6% | 0.3% | -14.4% | 11.4% | -12.7% |
| Other income | 1 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -2 | -2 | -3 | -5 | -1 | -4 |
| EPS (₹) | 1.56 | 1.52 | 2.24 | 3.60 | 1.07 | 3.24 |
| Revenue YoY | +39.7% | -37.8% | ||||
| Profit YoY | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 349 | 207 | 131 | 93 | 93 | 84 |
| EBITDA | 65 | 11 | 7 | -2 | 1 | -2 |
| Net profit | 40 | -1 | -9 | -12 | -11 | -13 |
| EPS (₹) | 38.51 | 0.04 | -6.48 | 9.42 | 8.43 | 10.15 |
| Revenue growth | -40.6% | -36.5% | -29.3% | +0.0% | – | |
| Profit growth | -101.7% | – | – | – | – | |
| Dividend / share (₹) | 1.00 | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -23.4% | – | – |
| Net profit | – | – | – |
| EPS | +495.1% | – | – |
| Share price | – | -14.8% (2y) | +8.8% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 64 | 53 |
| Borrowings | 80 | 78 |
| Cash & equivalents | 4 | 4 |
| Total assets | 230 | 209 |
| Fixed assets | 57 | 51 |
| Investments | 0 | 0 |
| Receivables | 67 | 68 |
| Inventory | 54 | 46 |
| Payables | 66 | 53 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -0 | 11 |
| Cash from investing | -2 | 1 |
| Cash from financing | 2 | -12 |
| Capex | 4 | 0 |
| Free cash flow | -4 | 11 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -19.4% | -21.0% |
| ROCE % | -4.9% | -3.9% |
| Debtor days | 262 | 267 |
| Inventory days | 331 | 279 |
| Payable days | 404 | 317 |
| Cash conversion cycle (days) | 189 | 229 |
| Working capital days | 69 | -15 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ANG | ₹43 cr | 3.2x | 0.8x | -22.8% | -5.8% | -2.3% | -23.4% | – |
Business segments (2026-06-30)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Pharmaceuticals | ₹14 cr | 86.8% | ₹-3 cr | -19.6% |
| Printing & Packaging | ₹2 cr | 13.2% | ₹-0 cr | -22.5% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2021-11-02 | Dividend | Interim Dividend Rs 1.0 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ANG |
| BSE code | 540694 |
| ISIN | INE236W01016 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.